Találati lista | Tudóstér

001-es BibID:	BIBFORM119263
035-os BibID:	(WoS)001177370100001 (Scopus)85186911726
Első szerző:	Székvölgyi Lóránt (biofizikus, biokémikus, sejtbiológus)
Cím:	Chromosomal R-loops : who R they? / Lóránt Székvölgyi
Dátum:	2024
ISSN:	2676-8615 2676-8607
Megjegyzések:	R-loops, composed of DNA-RNA hybrids and displaced single-stranded DNA, are known to pose a severe threat to genome integrity. Therefore, extensive research has focused on identifying regulatory proteins involved in controlling R-loop levels. These proteins play critical roles in preventing R-loop accumulation and associated genome instability. Herein I summarize recent knowledge on R-loop regulators affecting R-loop homeostasis, involving a wide array of R-loop screening methods that have enabled their characterization, from forward genetic and siRNA-based screens to proximity labeling and machine learning. These approaches not only deepen our understanding on R-loop formation processes, but also hold promise to find new targets in R-loop dysregulation associated with human pathologies.
Tárgyszavak:	Természettudományok Biológiai tudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk R-hurok, kromatinszerkezet
Megjelenés:	Biologia Futura. - 3 (2024), p. 1-8. -
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM091345
Első szerző:	Szöőr Árpád (orvos)
Cím:	From antibodies to living drugs : quo vadis cancer immunotherapy? / Szöőr Árpád, Szöllősi János, Vereb György
Dátum:	2021
ISSN:	2676-8615 2676-8607
Megjegyzések:	In the last few decades, monoclonal antibodies targeting various receptors and ligands have shown signifcant advance in cancer therapy. However, still a great percentage of patients experiences tumor relapse despite persistent antigen expression. Immune cell therapy with adoptively transferred modifed T cells that express chimeric antigen receptors (CAR) is an engaging option to improve disease outcome. Designer T cells have been applied with remarkable success in the treatment for acute B cell leukemias, yielding unprecedented antitumor activity and signifcantly improved overall survival. Relying on the success of CAR T cells in leukemias, solid tumors are now emerging potential targets; however, their complexity represents a signifcant challenge. In preclinical models, CAR T cells recognized and efciently killed the wide spectrum of tumor xenografts; however, in human clinical trials, limited antitumor efcacy and serious side efects, including cytokine release syndrome, have emerged as potential limitations. The next decade will be an exciting time to further optimize this novel cellular therapeutics to improve efector functions and, at the same time, keep adverse events in check. Moreover, we need to establish whether gene-modifed T cells which are yet exclusively used for cancer patients could also be successful in the treatment for other diseases. Here, we provide a concise overview about the transition from monoclonal antibodies to the generation of chimeric antigen receptor T cells. We summarize lessons learned from preclinical models, including our own HER2-positive tumor models, as well as from clinical trials worldwide. We also discuss the challenges we are facing today and outline future prospects taa, km
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Chimeric autoantibody receptor Immunotherapy Chimeric antigen receptor Bispecifc antibody Cell therapy Humanized antibody
Megjelenés:	Biologia Futura. - 72 : 1 (2021), p. 85-99. -
További szerzők:	Szöllősi János (1953-) (biofizikus) Vereb György (1965-) (biofizikus, orvos)
Pályázati támogatás:	K119690 OTKA FK132773 OTKA GINOP-2.3.2-15-2016-00044 GINOP Egyéb MTA ÚNKP-20-5-DE-48 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: